Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acute intravenous ketamine in treatment-resistant depression
jRCTs031210648Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of ketamine in treatment-resistant depression (TRD), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Completion rate of acute ketamine treatment. Started Mar 2022; status: completed.
02
Drugs
ketamine
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on jRCTs031210648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031210648.